Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Rhizoxin is a tubulin-binding anti-neoplastic agent which is active in a range of murine tumour models. The recommended schedule, of intravenous (i.v.) bolus administration at a dose of 2 mg m-2 every 3 weeks, has been assessed in three phase II trials of ovarian, renal and colorectal cancer. In general terms the drug was fairly well tolerated, but the response rate was disappointing: 0/18, colorectal cancer; 0/18, renal cancer; 1 partial response (PR)/17, ovarian cancer.

Original publication

DOI

10.1038/bjc.1995.498

Type

Journal article

Journal

Br J Cancer

Publication Date

11/1995

Volume

72

Pages

1267 - 1269

Keywords

Adult, Aged, Antineoplastic Agents, Phytogenic, Colorectal Neoplasms, Female, Humans, Kidney Neoplasms, Lactones, Macrolides, Middle Aged, Ovarian Neoplasms, Treatment Outcome